Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very conservative estimates from GMP and $2.50 price target:
https://gmpsecurities.bluematrix.com/sellside/EmailDocViewer?encrypt=5f72c1a0-9a72-46a1-98f2-9483af4aad66&mime=PDF&co=Gmpsecurities&id=noauthentication@bluematrix.com&source=libraryView&htmlToPdf=true
Emblem and Aphria: A Strategic Relationship in the Making
https://technical420.com/cannabis-article/emblem-and-aphria-strategic-relationship-making
The news smells pretty greeeeeen to me. GLTO$$$
News smews Will do nothing as long as the Powers to be keep sending all these MJ stocks down the toilet.
Emblem finalizes agreement to launch Emblem Germany in joint venture with Acnos Pharma
Agreement will see Emblem export to one of the world’s largest legal medical cannabis markets
TORONTO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX:EMMBF) ("Emblem" or the "Company"), today announced that, through its wholly-owned subsidiary Emblem Cannabis Corporation (“ECC”), it has signed a definitive agreement with German pharmaceutical wholesaler Acnos Pharma GmbH (“Acnos”) in respect to launching a joint venture under the name “Emblem Germany” (the “JV”) for the purpose of exporting Emblem-branded cannabis products from Canada into Germany. The JV – owned 60% by ECC and 40% owned by Acnos – will allow Emblem to commence exporting its products to Germany, with first deliveries expected to be made in mid-2019.
With a population of approximately 82.5 million and federal health insurance coverage for medical cannabis, Germany has created potentially one of the largest legal medical cannabis markets in the world. Subject to all applicable regulatory approvals, Emblem will supply the JV with cannabis oil for sale to German pharmacies, wholesalers and clinical labs for medical purposes.
“Finalizing and signing the definitive agreement with Acnos is a critical first step towards the establishment of a world-class distribution channel that extends internationally to key markets including Germany,” said Nick Dean, President and CEO of Emblem. “Our joint venture capitalizes on Acnos’ significant market knowledge, depth of understanding, and experience as a distributor with a strong track record in the pharma industry. We anticipate incredible demand for medical cannabis in this market and with that comes an opportunity for Emblem to provide physicians, pharmacists and patients with its trusted, high-quality, innovative, and patient-focused products. Emblem is well positioned to begin operations in an important international market.”
Emblem’s new 30,000 sq. ft. Product Innovation Centre, which includes a 5,000 sq. ft. laboratory built to GMP standards, is expected to be online in Q1 2019. This expanded footprint will provide significantly increased oil extraction capacity required for Emblem to meet the expected demands of the German market.
“Emblem’s medical division has positioned itself as an industry leader by innovating and producing high-quality pharmaceutical products,” said Maximillian Claudel, Co-Owner of Acnos. “From our experience, the long view of the German medical market is focused on oil extracts versus combustible products. Emblem’s experience innovating and delivering premium oil products to patients – along with the Company’s imminent growth in extraction capacity – make it an ideal international partner for Acnos.”
The export of products to Germany will be predicated upon Emblem satisfying applicable regulatory requirements for shipping cannabis products to Germany. This includes completion of Emblem’s GMP-certified laboratory in Ontario, followed by receipt of the European Medical Agency GMP certification which is expected to occur in mid-2019. Emblem will also require a Health Canada issued export permit and provisional import status from the German Bundesopiumstelle (Federal Narcotics Bureau) to import medical cannabis products into Germany.
Mr. Dean added, “This milestone further solidifies Emblem’s position as an industry leader in product innovation, branding and securing distribution networks. We are leveraging the Company’s strong medical history to create lucrative, sustainable partnerships that continue to put patients first. This will be achieved by building long-lasting relationships with some of the best partners the industry has to offer.”
About Acnos
Acnos Pharma GmbH is a pharmaceutical wholesaler based in Aachen, Germany. The company’s mission is to supply branded and non-branded medicines to pharmacies, wholesalers and other healthcare companies within the industry. By working closely with medical professionals and multinational manufacturers, Acnos strives for the highest and the latest standards and procedures to ensure the highest level of safety and quality. The quality management system and staff far exceed the industry's regulatory requirements and standards to ensure flawless, traceable and monitored product paths from the manufacturer to the customer.
About Emblem
Emblem is a fully integrated cannabis company focused on driving shareholder value through product innovation, brand relevance, and access to patient and consumer channels. Through its wholly-owned subsidiary Emblem Cannabis Corporation, Emblem is licensed to cultivate, process, and sell cannabis and cannabis derivatives in Canada under the Cannabis Act. Emblem’s state-of-the-art indoor cannabis cultivation facility and Product Innovation Centre is located in Paris, Ontario. Emblem is also the parent company of GrowWise Health Limited, one of Canada’s leading cannabis education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.
Except for Golden leaf, Emblem is the worst performer YTD according to this
https://seekingalpha.com/article/4213094-weekly-cannabis-report-sell-news-buy-dips?ifp=0
If you look. Majority of pot tickets have been in red the last few days
The CEO should be ashamed for the lack of news. This is a tree falling in the woods, and a BK would not surprise me. There is a reason no real news has come out since March. Makes you think a bankruptcy is near and the CEO doesn’t want to be sued. Too bad, I actually liked this stock.
You guys aren't getting any info here. Tons is happening and there is a whole world of discussion and statistics coming out. Will try to get some of it posted here, but go to Yahoo or reddit now to get caught up.
Emblem is killing it with initial sales. 10% of the dollar volume and 15% of the item sales over the weekend at Ontario Cannabis Store.
Does anyone know what is happening with this stock today? Also, what’s this Symbol thing is?
Going to go green. Hope y’all didn’t sell.
What a bunch of manipulated crap this sector is! Every MJ related stock in the red since this great day of legalization.
Emblem Corp. CEO Nick Dean welcomes Canada-wide adult-use cannabis legalizatio
https://ih.advfn.com/p.php?pid=nmona&article=78481598
There’s buying/trading/accumulating opportunities all over the sector this morning.
EMMBF/EMC—No fear here!
Lmao trash jist as expected! Cheers to bankruptcy in 2019!!
There seems to be ONE on the wrong side of this one! we all hope you move on.
Emblem Establishes Temporary “Patient Access Investment Fund” to Partially Cover Medical Cannabis Excise Tax
https://ih.advfn.com/p.php?pid=nmona&article=78465322
EMMBF
Nice day.
More to come.
It's GO Time For Emblem Corp.
https://technical420.com/cannabis-article/its-go-time-emblem-corp
Down nearly 50% for the year, they’re doing great! Lmao, failed execution of business plan, departure of most valuable executive, incredibly high patient acquisition cost (lmao at 4000), and cash burn on insider owned businesses. All part of the bankruptcy equation that will soon make EMMBF one of the worst MJ canadian stocks of all time! Enjoy!!
A Letter from Emblem’s President & CEO
TORONTO, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV:EMC, OTCQX:EMMBF) ("Emblem" or the "Company") delivers strategic vision to shareholders:
With adult-use legalization only days away, I am incredibly excited to provide an update on Emblem’s progress and plans for the future.
2018 has been a year of enormous change and evolution for the Emblem group of companies. We have made incredible strides and I couldn’t be prouder of the team we’ve assembled. Emblem continues to bring innovative products to market, most recently with the launch of Atmosphere oral sprays, and we’re firmly executing on our three-year strategy.
Most notably, in the third quarter we executed a strategic pivot in our approach to cannabis production, cancelling our capital-intensive production plans, and instead electing to take advantage of the significant wholesale supply capacity coming online industry-wide. This decision positions Emblem to benefit from what we expect to be falling prices in the production segment as commoditization increases. In practical terms this gives Emblem access to ample capacity, while freeing up our capital resources to focus on our passion for innovative value-added products where we already realize higher margin profiles.
Some of my proudest highlights from the past 10 months:
We took the bold step in signing a significant wholesale supply agreement with Aphria Inc., bringing our anticipated aggregate supply to almost 200,000 kg over five years (the “Aphria Supply Agreement”)
We were one of only six LPs to enter into a supply agreement with Shoppers Drug Mart, to help bring our medical products to patients across Canada
We have received provincial approvals to supply the Ontario, Alberta, British Columbia and Saskatchewan adult-use retail markets, with plans to keep growing Canada-wide in 2019
We made investments geared towards return on investment and established supply agreements with Fire & Flower and Starbuds Canada
We announced an agreement to form a joint venture with Acnos Pharma to bring our medical products to Germany, with an anticipated launch in 2019
We made advances in the product development of our extended release tablet in partnership with Canntab Therapeutics Inc.
We announced a partnership with GreenSpace Brands, a highly regarded consumer packaged goods company, to jointly produce CBD-infused health and beauty products as regulations allow
We launched our first adult-use brand, Symbl, which reinforces the core values of the Emblem brand and philosophy
We strengthened our management team with experienced talent from the beverage alcohol and pharmaceutical industries, including recently announcing the appointment of accomplished pharma executive Wayne Kreppner as President of Emblem’s Medical Division
We established a unique partnership with Durham College, through our patient education division GrowWise Health Limited, to educate future business leaders in the cannabis sector
We invested in DriveABLE to help support alternative methods to test cognitive impairment and support responsible use of cannabis products
We successfully delivered our first adult-use cannabis shipments to Ontario and Alberta at full committed quantities
We nearly doubled our active patient count, resulting in more than 5,000 patients now having access to Emblem’s medical cannabis products.
Finally, we have made significant progress on the completion of our new 30,000 sq. ft. Product Innovation Centre with a 5,000 sq. ft. GMP certified laboratory, scheduled to come online in early 2019
Needless to say, it’s been a busy year!
Emblem has continued to zig while the rest of the industry zagged – we’ve firmly repositioned the company to be a market leader in product innovation and branding. As we’ve seen in U.S. states that have legalized cannabis including Colorado, Washington and California, consumer demand has dramatically shifted away from raw cannabis in favour of innovative, convenient and smoke-free cannabis products that meet more consumer preferences.
Despite this, the industry predominantly continues to follow a cultivation-centered business model that requires cultivators to invest tens of millions of dollars into building and operating complex cannabis farming operations. As a result, massive amounts of capital are diverted away from what we believe could be the real drivers of future revenue growth and shareholder value – specifically research, development and commercialization of the next-generation of cannabis products and brands that consumers want. This is where we think that Emblem can differentiate.
Recognizing this new reality, Emblem is boldly charting its own path. Rather than following the pack, we made the bold decision to move away from cultivation and farming by signing the Aphria Supply Agreement and allowing Emblem to invest its energy and resources into developing revolutionary consumer products, building relevant brands and growing effective distribution channels.
Emblem intends to become a leading health and wellness focused consumer packaged goods company, providing the high quality cannabis products to patients and consumers domestically and internationally. To compete in this rapidly evolving industry, focus is critical to success. Emblem intends to leverage core competencies in innovation, marketing and brand development to launch innovative products and brands before our competitors, giving us a strong first-mover advantage in this nascent industry.
We are driven by three goals, focused on delivering the greatest shareholder returns:
To become a best-in-class producer of health and wellness focused products in the cannabis industry, driven by quality, consistency, and innovation.
To define our target market(s), execute within those markets, and become recognized as a ‘best brand’ in each market segment.
To build a business that is financially sustainable and profitable.
It is my belief that in the future, the notion of “production capacity” will be long forgotten in this sector. What will matter is how brands resonate with end users, and ultimately, their market share both domestically and globally. I believe that this brand recognition is likely the greatest opportunity for the sector and where the greatest shareholder value will be achieved.
Our recent supply commitments significantly amplify the value of our established products, brands and distribution. With our award-winning customer care and network of GrowWise cannabis education centres, we are a trusted source of cannabis products and information, and a collaborative industry leader that is committed to promoting responsible use. I believe that Emblem is well-positioned to realize our pioneering vision and meet the changing needs of consumers, patients and healthcare professionals now and into the future.
We’re Emblem and this is just the beginning.
Nick Dean
President & CEO
Emblem Corp.
https://finance.yahoo.com/news/letter-emblem-president-ceo-175120417.html
Thanks for the original link Macman
We now have the complete story to tell and the communication has begun. Get ready for a marketing blitz!
The one major wild card you didn't mention is the 12 hour tablet. Will be the companies single biggest revenue producer by a wide margin. This company will surprise even the bullish of the bulls here.
A Letter from Emblem’s President & CEO https://finance.yahoo.com/news/letter-emblem-president-ceo-175120417.html
Level headed analysis and I believe pretty easily attainable... excellent work, thank you!!
Emblem to supply British Columbia and Saskatchewan markets with high quality cannabis
Emblem supply to reach four key provinces
TORONTO, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX:EMMBF) (“Emblem” or the "Company") today announced that its wholly-owned subsidiary, Emblem Cannabis Corporation, one of Canada’s leading licensed producers of medical cannabis, has received approval to supply British Columbia and Saskatchewan with premium cannabis products under Emblem’s adult-use brand, Symbl.
In B.C., Emblem has been approved to supply cannabis to the BC Liquor Distribution Branch (“BCLDB”) – the sole, wholesale distributor of non-medical cannabis for the province that will operate standalone, public retail stores and provide online sales. In Saskatchewan, Emblem has been approved by the Saskatchewan Liquor and Gaming Authority (“SLGA”) to supply cannabis to the province’s private retail market. A curated range of Symbl-branded dried flower strains and premium cannabis oils are expected to be available in both provinces over the coming months.
“B.C. and Saskatchewan are important markets for Emblem’s continued domestic growth plans and we look forward to working with each province as a trusted partner to supply consumers with high-quality cannabis products that will meet their needs now and into the future,” said Nick Dean, CEO, Emblem Corp. “Emblem is focused on building a business for the long-term through product innovation, developing strong brands and enhanced distribution. With supply approvals in place across four key provinces – which also includes Ontario and Alberta – we continue to expand Emblem’s footprint and open up additional markets for our brands and products.”
“Leveraging Emblem’s existing strength in the medical market, we’re excited to introduce consumers in B.C. and Saskatchewan of legal age to Symbl. Symbl was created to offer a thoughtful brand experience for those seeking cannabis for recreational use that fits within a balanced lifestyle,” said Maria Guest, CMO, Emblem Corp. “Symbl is the first of several brands that Emblem intends to create to target a number of diverse consumer segments. As Canadians begin to navigate the new cannabis landscape, we believe that Symbl will become an established source for product information and cannabis education. We look forward to working with both provinces to build the foundation for a safe and responsible marketplace for consumers.”
Emblem has delivered in full its committed quantities to provincial wholesalers in Ontario and Alberta, meeting critical deadlines for the launch of cannabis legalization on October 17, 2018.
About Symbl
Upon legalization for adult-use, Symbl will offer a range of select strains in dried flower and cannabis oil. The line will cater to the full spectrum of Canadians who plan to explore the legal cannabis landscape. Symbl is the first brand in the adult-use cannabis division of Emblem. For more information, please visit www.symbl.ca.
About Emblem
Emblem, through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Emblem’s state-of-the-art indoor cannabis cultivation facility and research and development laboratory is located in Paris, Ontario. Led by an experienced management team of healthcare executives, accomplished marketing professionals, and cannabis experts, Emblem is focused on driving shareholder value through product innovation, brand relevance, and access to patient and consumer channels. Emblem is also the parent company of GrowWise Health Limited, one of Canada’s leading cannabis education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange. For more information, please visit www.emblemcorp.com.
For media inquiries, please contact:
Morgan Cates
H+K Strategies
416.413.4649
Morgan.cates@hkstrategies.ca
For investor inquiries, please contact:
Ethan Karayannopoulos
Investor Relations
Emblem Corp.
647.748.9696
ethank@emblemcorp.com
Alex Stojanovic
Chief Financial Officer
Emblem Corp.
416.923.1331
alexs@emblemcorp.com
https://globenewswire.com/news-release/2018/10/12/1620458/0/en/Emblem-to-supply-British-Columbia-and-Saskatchewan-markets-with-high-quality-cannabis.html
Okay, I finished my updated number-crunching and then searched for any analyst guidance. Came across a Canacord Genuity guidance dated May 30, 2018:
Revenue and Adj. EBITDA in FY2018 at $12.9 million and negative $576,000
Revenue and Adj. EBITDA for FY2019 at $62.6 million and $18.4 million
Might be a bit dated, but the analysts get info from the company that we aren't always privy to. I think Emblem probably quit giving out any type of guidance so we have no recent analyst predictions. I doubt it the Thompson Reuters forecasts have been updated recently. They are usually done after fiscal year earnings come out.
I came up with $78M revenue and $28M EBITDA for 2019 and I thought I was conservative when it came to limited revenue from Greenspace Brands and any revenue an Acnos partnership may see in Germany. While both will probably see some 2019 revenue, I am viewing that as gravy and not really counting it until 2020. I am actually quite pleased to not be too out of line compared to the Canacord Genuity numbers as they didn't have the benefit of pricing in the Aphria deal. I believe my numbers are very valid.
I am using 140M shares outstanding by the end of 2019 which gives us EBITDA of 20 cents a share. Pick a P/E you think is justified. We certainly aren't looking at a mature industry number of 10 to 15 for a P/E. 20 is a minimum under these circumstances and 30 is not unreasonable. You often see ridiculous P/Es at 100 or more when the growth is rapid. If we stay to a "reasonable" range of 20 to 30, we get a price per share of $4 - $6 or a market cap of $560M - $840M which brings us back to the $600M - $800M range I have been predicting for 2019.
That is how it works by the numbers. You don't choose a market cap and work it back. You do your best to predict revenue and EBITDA and then the numbers don't lie. No pie in the sky here. Very attainable numbers WITHOUT any big positive surprises.
Great day! Looks like the market agrees with me once again!
LMAO! John Stewart is in his 70s. We will retain his experience in an advisory role while bringing in someone with the passion for day to day productivity. Win Win.
Stewart sees the writing on the wall, bankruptcy in 2019. Emblem isn’t even a top 10 LP now and will be back under $1 soon enough, then the Q filings shortly thereafter! Enjoy!
This is definitely a plus... no spin required.
We all knew John Stewart was a figurehead only. They always brushed aside questions about his day to day duties and always said he "oversaw" this and that. Now they finally made it official. He will still oversee the division and lend his experience and industry clout when and where needed. Nothing has changed, but his title.
It is a very GOOD thing that they are bringing in someone who will devote more time and passion to the day to day operations. This is just what we need:
An accomplished pharmaceutical industry executive, Mr. Kreppner will bring 20 years of research and development, regulatory affairs and senior management expertise to Emblem’s Medical Division. Prior to joining Emblem, Mr. Kreppner was President and Chief Operating Officer at Concordia International Corporation where he oversaw triple-digit growth of both revenue and EBITDA. He also served as Vice President, Technical Operations at Trimel Pharmaceuticals, and held various senior roles in technical operations and regulatory affairs at Biovail Corporation.
Finally Emblem will actually move towards these things:
In accepting his appointment, Mr. Kreppner said: “There is an incredible opportunity to further develop the role of cannabis and cannabinoids in medical treatment. The goal at Emblem is to identify innovative ways to bring pharmaceutical formulations of cannabis to patients, supported by clinical evidence. I am honoured to join Emblem’s medical team and look forward to contributing to the company’s success.”
No knock on Stewart. Emblem Medical just didn't become what many had envisioned. We should be at the forefront of clinical trials. We need to become the type of company that a pharmaceutical company and not another cannabis company wants to acquire.
Very excited to see this new focus and some fresh talent to implement it!
Emblem Appoints New Medical Division President
http://emblemcorp.com/blog/emblem-bolsters-medical-division-to-support-growth-and-product-innovation-with-appointment-of-wayne-kreppner-as-president/
Toronto, October 11, 2018 – Emblem Corp. (TSXV: EMC, OTCQX:EMMBF) (“Emblem” or the “Company”) today announced additional leadership and operational resources to support the rapid growth of its medical division and associated new product innovations. Emblem Director and current Medical Division President, John H. Stewart, welcomes Wayne Kreppner to the Company as the Division’s new President. Mr. Stewart will oversee the Division in an advisory capacity and will remain a member of Emblem’s Board of Directors. Mr. Kreppner will begin November 1, 2018. The appointment of Mr. Kreppner is subject to the normal course approvals of the TSX Venture Exchange.
An accomplished pharmaceutical industry executive, Mr. Kreppner will bring 20 years of research and development, regulatory affairs and senior management expertise to Emblem’s Medical Division. Prior to joining Emblem, Mr. Kreppner was President and Chief Operating Officer at Concordia International Corporation where he oversaw triple-digit growth of both revenue and EBITDA. He also served as Vice President, Technical Operations at Trimel Pharmaceuticals, and held various senior roles in technical operations and regulatory affairs at Biovail Corporation.
Over the past three years, Mr. Stewart led the creation of Emblem’s Medical Division and delivered several firsts for the Company, including its partnership with Canntab Therapeutics Inc. to develop oral extended-release cannabinoid tablets. Mr. Stewart also oversaw the design and build-out of Emblem’s extraction, analytical and product development facilities, the launch of Emblem’s line of four strain specific cannabis oils and most recently the launch of Atmosphere, Emblem’s line of metered-dose cannabis oil oral sprays.
“In a relatively short time, Emblem has established an extremely capable Medical Division. Wayne will bring with him a wealth of proven experience in developing, launching and commercializing pharmaceutical products. His ability to simultaneously manage the many aspects of new product development, clinical research and production will be an important addition to the Medical Division and Emblem’s overall commitment to product innovation,” said John H. Stewart, outgoing Division President. “I look forward to working closely with Wayne and existing members of the medical team.”
“Emblem’s Medical Division is a leader in product innovation. Emblem has always had a patient-first approach, developing new products that support patients’ health goals and that physicians are confident in prescribing. Wayne shares this mindset and we’re thrilled to bring his proven experience and leadership to our world-class team,” said Nick Dean, CEO, Emblem Corp.
In accepting his appointment, Mr. Kreppner said: “There is an incredible opportunity to further develop the role of cannabis and cannabinoids in medical treatment. The goal at Emblem is to identify innovative ways to bring pharmaceutical formulations of cannabis to patients, supported by clinical evidence. I am honoured to join Emblem’s medical team and look forward to contributing to the company’s success.”
Additional changes to Emblem Corp Leadership
Further changes to Emblem’s leadership team include the departure of Daniel Saperia, Chief Operating Officer, effective November 1, 2018. Mr. Saperia’s tenure at Emblem began in 2014 shortly after the Company’s founding, and includes a number of key accomplishments, including overseeing a 100% fill rate of first orders to Emblem’s provincial partners. Mr. Saperia will continue to provide support during a transition period until December 31, 2018.
“I want to personally thank Danny for his tremendous contributions to Emblem over the last four years as our first Chief Operating Officer. In his time at Emblem, Danny has been directly responsible for building the foundation upon which the Company can now prosper and grow into its next phase,” said Dean. “Under his leadership, we have seen significant improvements across our production, cultivation and supply chain. Danny is a fabulous mentor, coach, team leader and friend to many of us, and we wish him all the best.”
“I’m incredibly proud of Emblem’s accomplishments over the past four years and look forward to seeing the Company continue to grow in the future,” said Mr. Saperia. “I’m grateful to have played a role in Emblem’s evolution and wish the team continued success.”
Something was up yesterday 100000 bid and lot of after hour catchup. Some new money just bought in. We are fune here.
?? right back to loading zone. This is what a Canadian MJ turd looks like folks!
The Penny Man King says make this part of your portfolio before it is too late.
Does anyone know what the early morning trades are all about? Seems to me someone buys in enough to keep this down right now??
A lot of people have put money in this company. And like I said I think the old guys from Purdue are little bit greedy possibly. And I think it's pissed off a lot of the big pockets that used to be in here. Let's hope for the best here they should be over five dollars by now.
I agree. I am certain that they have strong connections in the cannabis world and the medical world. Top 10 cannabis stock and in the end, maybe top 5.
I'm thinking we get a 160/170 pop in October November and then December January we will be over two dollars if it's anything like it has been in the past. However with October legalization not sure what it's going to do. All in my humble opinion on the conservative side
I am hoping the time release is some how patented. I am sure the Perdue guys as well well as Stewart have stong conections in the medical and distribution world. October will be interesting. We should get aome nice consolidation and build up for the new year. Been waiting a long while for these guys to step up the PR game. This year has been much better than last. GLA
Does anybody have a guess on the EOY closing price. ?
Investor Center for Emblem Corp.
emblemcorp.com/investor-center/
Another interesting article
https://lakenormanreview.com/a-look-at-the-health-of-emblem-corp-tsxvemcs-shares/
Followers
|
44
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1282
|
Created
|
03/03/17
|
Type
|
Free
|
Moderators |
We love our Mothers! Finding the best Mother plant to breed each of our cannabis strains is the first step to uncovering the perfect phenotype. We begin by growing a full room of mothers of a single strain. We carefully watch each plant grow, taking note of their unique qualities. As each plant is harvested, it’s meticulously tested for the natural cannabinoids and terpenes that will provide the greatest patient relief. After the ultimate Mother phenotype is selected, we begin tending to her daughters with the same care and attention. Just as nature provides us with the benefits of cannabis, it has its own way of controlling the natural predators. Our first defense is a holistic one, using organic solutions to ensure our strains grow healthy and true to their innate plant powers. We also employ various strategies, like elevating the CO2 levels, making our plants grow bigger and more robust. The pungent terpene aroma and flavour is the telltale difference naturally grown makes.
We’re just like you. Either by chance, fate or on the advice of a physician, we discovered the medical benefits of cannabis. It naturally enhances our entire state of wellbeing for optimal living. That’s why we created Emblem. Together we can celebrate feeling whole, and a whole lot better than before. We’re not a giant, disconnected corporation. We’re a team of passionate growers carefully tending batches of thoughtfully curated cannabis strains, widely regarded for their efficacy, flavour and effect. We cultivate these strains into medical products that enhance your wellbeing, helping you transform your life and attain extraordinary health. Join us, for better living.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |